Institutions bought Pingtan Development and 17 other stocks today, selling Eastroc Beverage for 363 million yuan36Kr·Mar 31, 2026 at 10:25 AM688308-5.40%605499+1.64%
"A-Share Focus" Staidson BioPharm plummets 8.5%, the third-largest shareholder plans to reduce holdingsetnet·Nov 6, 2025 at 02:33 AM300204-1.47%
Staidson BioPharm today hit a 20% limit up, with 5 institutional special seats net buying 229 million yuanZhitong·Oct 31, 2025 at 08:25 AM300204-1.47%
Staidson BioPharm released its performance for the first three quarters, with a net loss attributable to the parent company of 30.6895 million yuanZhitong·Oct 28, 2025 at 10:56 AM300204-1.47%
Staidson BioPharm: Application for stock issuance to specific objects accepted by Shenzhen Stock ExchangeZhitong·Oct 26, 2025 at 08:17 AM300204-1.47%
Innovative drug concept stocks continue to be active, HUAPONT LIFE SCIENCES hits the limit upZhitong·Oct 17, 2025 at 01:44 AM300683-4.03%0020040.00%
The pharmaceutical sector fell at the beginning of trading, with SUNFLOWER dropping 10%Zhitong·Sep 26, 2025 at 01:33 AM300204-1.47%600276-0.79%
10 drugs have been suspended from procurement qualifications, involving Staidson BioPharm, Baillie Pharmaceutical, and other companiesZhitong·Sep 17, 2025 at 06:59 AM300204-1.47%
The concept of innovative drugs has rebounded, with Chimin gaining 6 limit-ups in 12 days, Staidson BioPharm rising over 7%, Hotgen increasing over 5%, and stocks like Medicilon, Cosunter, and BrightGene also seeing gainsZhitong·Sep 11, 2025 at 02:20 AM603222-1.83%300204-1.47%
Staidson BioPharm: Xiangtang Group reduced its holdings by 3.3607 million shares of the companyZhitong·Sep 10, 2025 at 10:42 AM300204-1.47%
Staidson BioPharm plans to raise no more than 1.253 billion yuan through a private placement of sharesZhitong·Sep 9, 2025 at 09:09 AM300204-1.47%
2025 Fund Mid-Year Report Insight: Pharmaceuticals, Banks, and Electronics Become Key Areas for Increased Holdings, Staidson BioPharm Fund's Shareholding Ratio Ranks FirstZhitong·Sep 2, 2025 at 06:36 AM002940-2.93%300204-1.47%
Innovative drug concept stocks fell in the afternoon, with Staidson BioPharm down over 10%Zhitong·Sep 2, 2025 at 05:17 AM002940-2.93%3001580.00%
Staidson BioPharm released its performance for the first half of the year, with a net loss attributable to the parent company of 24.6356 million yuanZhitong·Aug 25, 2025 at 11:41 AM300204-1.47%
A-share innovative drug concept stocks fluctuated upward, EASTON BIOPHARMACEUTICALS and BioKangtai rose over 10%, Thalys, Staidson BioPharm, ALK, and ZHIFEI-BIOL followed suitZhitong·Aug 25, 2025 at 01:41 AM300122-0.72%688513+2.69%